Related Experiment Video
Updated: Aug 19, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
[Carcinoma of the vulva: a report of treatment]
1Department of Gynecological Oncology, Cancer Institute (Hospital), Peking Union Medical University, Chinese Academy of Medical Sciences, Beijing 100021, China.
Objective:
To analyse the outcome of various treatments for vulvar cancer and to investigate the characteristics of the recurrence and metastasis.
Methods:
A total of 309 patients with carcinoma of vulva were analyzed retrospectively.
Results:
The overall 5-year survival rate was 67.9%. That for stage I, II, III and IV was 86.9%, 82.5%, 59.2% and 43.6%, respectively. Treatment failure was seen in 49.8% of the treated cases, and it occurred within 2 years after primary treatment in the majority of the cases. Inguinal and pelvic recurrences, and distant metastases occurred within 2 years, while local recurreuce mostly after 2 years. Recurrence rate was not related to age of the patients. For stage I cancer, there was no difference in the results of different methods of treatment, but for stage II cancer, wide local resection plus inguinal lymphadenectomy was a better choice. In patients with regional lymph node metastases treated by nodal resection, it was less likely to recur than did radiotherapy. If no nodal involvement, the outcome of the two types of treatment was not different. Higher dose of radiation (Dm > or = 60 Gy) was better than lower dose (40-50 Gy) for prevention of recurrence.
Conclusion:
For early stage vulvar cancer, in addition to radical resection of vulva, preventive dissection of inguinal lymph nodes, or full dose radiation of the inguinal region, leads to better therapeutic results. For advanced cases, radical resection of the primary tumor with pre- and post-operative radiation, and inguinal lymph nodal disection, whenever possible, should be performed.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Treatment Resistent Cancers
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

